

**EFFECT**  
A study on quality and effectiveness of  
endometrial cancer treatment in Belgium

Belgian Cancer Registry



---

**EFFECT**  
General feedback  
2015

---



## Table of contents

Descriptives.....	4
Number of registrations.....	4
Age distribution.....	8
Topography and Histology.....	10
Clinical stage.....	12
Pathological stage.....	15
Surgery.....	18
Lymphadenectomy.....	20
Hormone receptor status primary tumour.....	22
Adjuvant treatments.....	25
Quality indicators.....	27
QI 1: Tumour board review/multidisciplinary opinion.....	27
QI 2: ASA and/or WHO score reported.....	28
QI 2a: Overall proportion of patients whose WHO and/or ASA score is reported.....	28
QI 2b: Overall proportion of patients whose WHO score is reported.....	29
QI 2c: Overall proportion of patients whose ASA score is reported.....	30
QI 3: Specific WHO histology code among patients undergoing surgery.....	31
QI 4: Operated patients with pre-operative biopsy.....	32
QI 5: Tumour grade available from biopsy for treatment decision.....	33
QI 6: cStage I patients with surgical intervention TH/BSO.....	34
QI 7: Adnexal invasion reported for patients undergoing surgery.....	35
QI 8: Minimally invasive surgery for clinical stage I patients.....	36
QI 9: Myometrial invasion available for treatment decision.....	37
QI 9a: Myometrial invasion available for treatment decision, when analysis resection specimen available.....	37
QI 9b: Myometrial invasion available for treatment decision.....	38
QI 10: Cervical stromal invasion available for treatment decision.....	39
QI 10a: Cervical stromal invasion available for treatment decision, when analysis resection specimen available.....	39
QI 10b: Cervical stromal invasion available for treatment decision.....	40
QI 11: Omentectomy among stage I/II serous or clear cell carcinomas or carcinosarcomas.....	41
QI 12: TH (+/- BSO) among operated patients with uterine leiomyosarcoma or endometrial stromal sarcoma.....	42
QI 13: Number of para-aortic lymph nodes with metastasis specified for patients undergoing surgery.....	43
QI 14: Localization of removed lymph nodes specified among patients undergoing surgery.....	44
QI 15: Number of pelvic lymph nodes harvested specified among patients with pelvic lymphadenectomy.....	45
QI 16: Number of para-aortic lymph nodes harvested specified among patients with para-aortic lymphadenectomy.....	46
QI 17: Number of metastatic pelvic lymph nodes for whom extracapsular extension specified among patients with pelvic lymphadenectomy.....	47
QI 18: Stage II patients with TH/BSO and pelvic lymph node dissection.....	48
QI 19: Stage I and grade 3 patients who had at least pelvic lymphadenectomy.....	49
QI 20: Pelvic and para-aortic lymphadenectomy among clinical stage IIIA patients with TH/BSO as type of surgery.....	50
QI 21: Lymphadenectomy among type I carcinomas invading less than 50% of the myometrium.....	51
QI 22: Pelvic lymphadenectomy among stage I/II serous or clear cell carcinomas or carcinosarcomas.....	52
QI 23: Lymphadenectomy among patients with uterine leiomyosarcoma or endometrial stromal sarcoma (low grade).....	53
QI 24: Known hormone receptor status among metastatic or recurrent endometrioid adenocarcinoma patients.....	54
QI 24a: pM=1 patients.....	54
QI 24b: cM=1 patients.....	55
QI 25: Receptor status status available for treatment decision among patients with endometrial stromal sarcomas.....	56
QI 26: Waiting time for adjuvant therapy maximal 60 days.....	57
QI 26a: Proportion of operated patients receiving subsequent/adjuvant anticancer treatment.....	57
QI 26b: Waiting time for adjuvant therapy maximal 60 days.....	58
QI 27: Proportion of IMRT or 3DCRT.....	59
QI 28: Radiotherapy for cStage I or II patients without surgery.....	60
QI 29: Adjuvant RT for pStage I patients having at least 2 risk factors with surgery but no lymphadenectomy.....	61
QI 30: Vaginal brachytherapy among pStage I patients having at least 2 risk factors with surgery and adjuvant RT.....	62
QI 31: Adjuvant radiotherapy among operated patients at low risk of recurrence.....	63
QI 32: Radiotherapy among operated patients with stage I and low grade endometrial stromal sarcoma or leiomyosarcoma.....	64
QI 33: Platinum-based drugs among patients with adjuvant chemotherapy.....	65
QI 34: Chemotherapy among advanced cancer patients with surgery.....	66
QI 35: Chemotherapy among pStage I patients having at least 2 risk factors with surgery and no lymphadenectomy.....	67
QI 36: Adjuvant chemotherapy among operated patients at low risk of recurrence.....	68
QI 37: Hormone therapy among operated endometrioid pStage IVB patients.....	69
QI 38: Hormone therapy among operated patients with clinical or pathological stage II to IV endometrial stromal sarcomas.....	70
QI 39: Post-operative 30-day mortality.....	71
QI 40: Observed survival.....	72
QI 41: Disease-free survival at 1 year.....	75

## 1. Descriptives


### 1.1. Number of registrations

#### 1.1.1. Number of registrations by hospital

**Table 1. Number of registrations per hospital**


Hospital code	New registrations								Follow-up registrations	
	2012		2013		2014		Total			
	N	%	N	%	N	%	N	%	N	%
Z01	0	0.0	8	1.2	27	3.8	39	1.8	34	1.5
Z02	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10
Z03	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10
Z04	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10
Z05	16	2.3	8	1.2	0	0.0	24	1.1	4	0.1
Z06	11	1.6	10	1.5	10	1.4	40	1.8	58	2.5
Z07	9	1.3	2	0.3	2	0.2	14	0.6	5	0.2
Z08	15	2.2	13	2.0	15	2.1	43	1.9	55	2.4
Z09	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10
Z10	15	2.2	18	2.7	18	2.5	54	2.4	78	3.4
Z11	5	0.7	7	1.0	9	1.2	24	1.1	35	1.5
Z12	25	3.7	24	3.6	34	4.8	91	4.2	61	2.7
Z13	7	1.0	3	0.4	4	0.5	14	0.6	14	0.6
Z14	4	0.5	8	1.2	6	0.8	18	0.8	3	0.1
Z15	7	1.0	8	1.2	9	1.2	26	1.2	36	1.6
Z16	30	4.4	22	3.3	8	1.1	68	3.1	64	2.8
Z17	38	5.6	17	2.6	35	5.0	107	4.9	40	1.7
Z18	26	3.8	9	1.3	25	3.5	67	3.0	54	2.4
Z19	21	3.1	16	2.4	19	2.7	56	2.5	49	2.1
Z20	0	0.0	27	4.1	0	0.0	27	1.2	19	0.8
Z21	38	5.6	48	7.3	42	6.0	138	6.3	188	8.4
Z22	7	1.0	14	2.1	7	1.0	28	1.2	24	1.0
Z23	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10
Z24	0	0.0	10	1.5	8	1.1	19	0.8	11	0.4
Z25	3	0.4	13	2.0	29	4.1	45	2.0	28	1.2
Z26	3	0.4	2	0.3	6	0.8	14	0.6	5	0.2
Z27	96	14.3	81	12.4	91	13.0	285	13.1	302	13.5
Z28	26	3.8	13	2.0	12	1.7	60	2.7	84	3.7
Z29	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10
Z30	27	4.0	20	3.0	8	1.1	55	2.5	114	5.0
Z31	9	1.3	8	1.2	11	1.5	31	1.4	52	2.3
Z32	17	2.5	24	3.6	16	2.3	62	2.8	90	4.0

Hospital code	New registrations								Follow-up registrations	
	2012		2013		2014		Total			
	N	%	N	%	N	%	N	%	N	%
Z33	16	2.3	6	0.9	5	0.7	28	1.2	22	0.9
Z34	23	3.4	21	3.2	9	1.2	53	2.4	69	3.0
Z35	2	0.2	0	0.0	56	8.0	79	3.6	60	2.6
Z36	42	6.2	32	4.9	25	3.5	101	4.6	187	8.3
Z37	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10
Z38	6	0.8	11	1.6	6	0.8	24	1.1	9	0.4
Z39	13	1.9	14	2.1	0	0.0	27	1.2	0	0.0
Z40	0	0.0	1	0.1	10	1.4	13	0.6	2	0.0
Z41	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10
Z42	4	0.5	5	0.7	1	0.1	10	0.4	9	0.4
Z43	9	1.3	12	1.8	9	1.2	31	1.4	43	1.9
Z44	19	2.8	24	3.6	20	2.8	63	2.9	62	2.7
Z45	0	0.0	22	3.3	24	3.4	46	2.1	55	2.4
Z46	10	1.4	6	0.9	0	0.0	16	0.7	38	1.6
Z47	1	0.1	7	1.0	8	1.1	18	0.8	21	0.9
Z48	0	0.0	1	0.1	13	1.8	14	0.6	0	0.0
Z49	0	0.0	15	2.3	6	0.8	21	0.9	0	0.0
Z50	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10
Z51	10	1.4	0	0.0	2	0.2	14	0.6	0	0.0
Z52	24	3.5	7	1.0	18	2.5	55	2.5	61	2.7
Z53	4	0.5	5	0.7	3	0.4	12	0.5	17	0.7
Z54	24	3.5	17	2.6	5	0.7	46	2.1	64	2.8
Z55	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10	N<10
<b>Total</b>	<b>668</b>	<b>100.0</b>	<b>650</b>	<b>100.0</b>	<b>695</b>	<b>100.0</b>	<b>2,163</b>	<b>100.0</b>	<b>2,236</b>	<b>100.0</b>



**Figure 1. Distribution of the total number of registrations by hospital (new diagnosis) ( $N_{\text{total}} = 2,163$ )**

### 1.1.2. Number of registrations per incidence year



**Figure 2. Distribution of the number of registrations by incidence year (new diagnosis) ( $N_{\text{total}} = 2,163$ ).**

## 1.2. Age distribution

**Table 2. Age distribution of the patients registered with a new diagnosis**

Hospital code	Age (years)				
	N	Mean	Median	Min	Max
H01	54	68	67	38	90
H02	14	67	66	53	84
H03	N<10	N<10	N<10	N<10	N<10
H04	53	68	67	50	89
H05	14	66	67	51	85
H06	14	70	69	49	94
H07	68	68	70	27	98
H08	12	68	66	61	79
H09	39	68	70	49	84
H10	N<10	N<10	N<10	N<10	N<10
H11	27	69	69	51	89
H12	43	69	71	42	87
H13	46	70	72	46	96
H14	19	67	72	37	91
H15	16	67	65	54	87
H16	28	74	78	53	89
H17	55	71	71	45	95
H18	14	73	72	60	89
H19	N<10	N<10	N<10	N<10	N<10
H20	63	69	70	40	90
H21	18	71	72	51	90
H22	28	69	72	44	89
H23	107	67	67	44	85
H24	56	67	67	48	88
H25	79	67	67	33	88
H26	101	70	71	38	89
H27	24	64	63	50	79
H28	N<10	N<10	N<10	N<10	N<10
H29	N<10	N<10	N<10	N<10	N<10
H30	N<10	N<10	N<10	N<10	N<10
H31	62	70	71	51	91
H32	14	69	68	52	89
H33	24	76	79	56	94
H34	N<10	N<10	N<10	N<10	N<10
H35	N<10	N<10	N<10	N<10	N<10
H36	10	74	74	60	93



Age (years)					
Hospital code	N	Mean	Median	Min	Max
H37	31	66	67	22	90
H38	46	64	67	24	88
H39	67	67	67	43	94
H40	91	68	68	39	91
H41	60	67	69	46	93
H42	26	72	75	45	90
H43	138	69	71	42	89
H44	40	65	67	35	85
H45	24	71	72	51	93
H46	45	64	67	34	86
H47	285	66	68	31	98
H48	13	70	71	51	88
H49	N<10	N<10	N<10	N<10	N<10
H50	N<10	N<10	N<10	N<10	N<10
H51	31	67	74	39	92
H52	21	70	72	33	85
H53	55	69	70	45	89
H54	27	64	66	35	82
H55	18	69	68	38	88
<b>Total</b>	<b>2,163</b>	<b>68</b>	<b>69</b>	<b>22</b>	<b>98</b>

### 1.3. Topography and Histology

#### 1.3.1. Topography

**Table 3. Distribution of the topography**

Topography			
ICDO-3 code	Name	N	%
C54.0	Isthmus uteri	3	0.1
C54.1	Endometrium	1,920	88.8
C54.2	Myometrium	35	1.6
C54.3	Fundus uteri	21	1.0
C54.8	Overlapping lesion of corpus uteri	7	0.3
C54.9	Corpus uteri	149	6.9
C55.9	Uterus, NOS	28	1.3
<b>Total</b>		<b>2,163</b>	<b>100.0</b>


#### 1.3.2. Histology

**Table 4. Distribution of the histology**


Histology type			
ICDO-3 code	Name	N	%
8000/3	Neoplasm. malignant	7	0.3
8010/3	Carcinoma, NOS	6	0.3
8020/3	Carcinoma, undifferentiated, NOS	6	0.3
8041/3	Small cell carcinoma, NOS	5	0.2
8070/3	Squamous cell carcinoma, NOS	4	0.2
8140/3	Adenocarcinoma, NOS	98	4.5
8262/3	Villous adenocarcinoma	6	0.3
8263/3	Villoglandular adenocarcinoma	6	0.3
8310/3	Clear cell adenocarcinoma, NOS	50	2.3
8323/3	Mixed cell adenocarcinoma	24	1.1
8380/3	Endometrioid adenocarcinoma, NOS	1,541	71.2
8382/3	Endometrioid adenocarcinoma, secretory variant	5	0.2
8441/3	Serous carcinoma, NOS	150	6.9
8480/3	Mucinous adenocarcinoma	27	1.2
8481/3	Mucin-producing adenocarcinoma	1	0.0
8560/3	Adenosquamous carcinoma	14	0.6
8570/3	Adenocarcinoma with squamous metaplasia/differentiation	18	0.8
8800/3	Sarcoma, NOS	5	0.2

<b>Histology type</b>			
<b>ICDO-3 code</b>	<b>Name</b>	<b>N</b>	<b>%</b>
8805/3	Undifferentiated stromal sarcoma	4	0.2
8890/3	Leiomyosarcoma, NOS	41	1.9
8891/3	Epithelioid leiomyosarcoma	4	0.2
8930/3	Endometrial stromal sarcoma, high grade / NOS	17	0.8
8931/3	Endometrial stromal sarcoma, low grade	19	0.9
8933/3	Adenosarcoma	9	0.4
8950/3	Carcinosarcoma, NOS	14	0.6
8980/3	Malignant Mullerian mixed tumour	82	3.8
<b>Total</b>		<b>2,163</b>	<b>100.0</b>


#### 1.4. Clinical stage



**Figure 3. Specification of the clinical stage (all patients, 8000/3 not included) ( $N_{\text{total}} = 2,163$ )**




**Figure 4. Distribution of the clinical stage for the group of carcinomas (carcinosarcomas included) ( $N_{\text{total}} = 1,309$ ). For an additional 5 patients a cT0N0M0 was completed.**




**Figure 5. Distribution of the clinical stage for the group of sarcomas ( $N_{\text{total}} = 31$ ). For 68 patients, the cTNM was not specified**

### 1.5. Pathological stage




**Figure 6. Specification of the pathological stage (carcinomas and sarcomas) for patients with surgical resection ( $N_{\text{total}} = 1,951$ )**



**Figure 7. Distribution of the pathological stage for the group of carcinomas (carcinosarcomas included) ( $N_{\text{total}} = 1,780$ )**






**Figure 8. Distribution of the pathological stage for the group of sarcomas ( $N_{\text{total}} = 59$ )**

## 1.6. Surgery

### 1.6.1. Type of surgery



**Figure 9. Overview of the type of surgery performed for the patients who underwent a surgical intervention (N<sub>total</sub> = 1,963)**


## 1.6.2. Type of surgical procedures

**Table 5. Overview of the types of surgical procedures**

Type of performed surgical procedure(s)	N	%
Laparoscopy, non robot-assisted	714	36.4
Laparoscopy, non robot-assisted + Robot-assisted laparoscopy	1	0.1
Laparotomy, conversion after laparoscopy	57	2.9
Laparotomy, conversion after laparoscopy + Laparoscopy, non robot-assisted	2	0.1
Laparotomy, standard	693	35.3
Other	40	2.0
Robot-assisted laparoscopy	210	10.7
Vaginal hysterectomy	121	6.2
Vaginal hysterectomy + Laparoscopy, non robot-assisted	112	5.7
Vaginal hysterectomy + Laparotomy, conversion after laparoscopy	2	0.1
Vaginal hysterectomy + Laparotomy, standard	7	0.4
Vaginal hysterectomy + Laparotomy, standard + Laparoscopy, non robot-assisted	1	0.1
Vaginal hysterectomy + Robot-assisted laparoscopy	3	0.2
<b>Total</b>	<b>1,963</b>	<b>100.0</b>


## 1.7. Lymphadenectomy

### 1.7.1. Lymphadenectomy performed?



**Figure 10. Distribution of the lymphadenectomy procedure ( $N_{\text{total}} = 2,156$ ).**

### 1.7.2. Level of lymphadenectomy performed



**Figure 11. Distribution of the level of the lymphadenectomy performed ( $N_{\text{total}} = 942$ ).**


### 1.7.3. Number of resected lymph nodes

**Table 6. Overview of the number of resected lymph nodes by indicated level**

Lymph node level	N		Min	Median	Max
	Specified	Not specified			
Pelvic	851	26	0	18	73
Para-aortic	203	12	0	12	58


## 1.8. Hormone receptor status primary tumour

### 1.8.1. Basis of hormone receptor status determination




**Figure 12. Overview of the type of specimen used for the hormone receptor test ( $N_{\text{total}} = 2,163$  and  $2,163$  for ER and PR respectively)**

### 1.8.2. Conclusion of the ER receptor test



**Figure 13. Overview of the conclusion of the ER receptor test ( $N_{\text{total}} = 990$ ). For 9 patients, the conclusion of the analysis on the resection specimen was not completed.**

### 1.8.3. Conclusion of the PR receptor test




**Figure 14. Overview of the conclusion of the PR receptor test ( $N_{\text{total}} = 921$ ). For 6 patients, the conclusion of the analysis on the resection specimen was not completed.**



## 1.9. Adjuvant treatments

### 1.9.1. Type of adjuvant treatment



**Figure 15. Overview of the type of adjuvant treatments performed for the patients who underwent a surgical intervention and for whom FU information on adjuvant treatment is available ( $N_{\text{total}} = 1,176$ )**

## 1.9.2. Type of adjuvant treatment

**Table 7. Overview of the types of adjuvant treatment**

Type of adjuvant treatment	N	%
Brachytherapy	128	31.1
Brachytherapy + Chemotherapy	5	1.2
Chemotherapy	90	21.8
Chemotherapy + Hormonal therapy	4	1.0
External Beam RT	48	11.7
External Beam RT + Brachytherapy	55	13.3
External Beam RT + Brachytherapy + Chemotherapy	35	8.5
External Beam RT + Brachytherapy + Chemotherapy + Hormonal therapy	1	0.2
External Beam RT + Brachytherapy + Hormonal therapy	1	0.2
External Beam RT + Chemotherapy	33	8.0
External Beam RT + Hormonal therapy	1	0.2
Hormonal therapy	11	2.7
<b>Total</b>	<b>412</b>	<b>100.0</b>

## 2. Quality indicators

Patients who were under treatment for a primary tumour within 5 years before their corpus uteri tumour diagnosis were excluded for the QI calculation.

### 2.1. QI 1: Overall proportion of patients who had at least one tumour board review/multidisciplinary opinion during the management of their disease

Table 8. QI 1

	QI 1 percentage	
	% (n/N)	95% CI
EFFECT	98.3 (2025/2061)	[97.6, 98.7]




Figure 16. Funnel plot for QI 1

2.2. QI 2: Overall proportion of patients whose ASA and/or WHO score is reported

2.2.1. QI 2a: Overall proportion of patients whose WHO and/or ASA score is reported

Table 9. QI 2a - WHO or ASA reported

QI 2a - WHO or ASA reported percentage		
	% (n/N)	95% CI
EFFECT	98.7 (2034/2061)	[98.1, 99.1]




Figure 17. Funnel plot for QI 2a - WHO or ASA reported

2.2.2. QI 2b: Overall proportion of patients whose WHO score is reported

Table 10. QI 2b - WHO reported

	QI 2b - WHO reported percentage	
	% (n/N)	95% CI
EFFECT	97.6 (2012/2061)	[96.9, 98.2]




Figure 18. Funnel plot for QI 2b - WHO reported

2.2.3. QI 2c: Overall proportion of patients whose ASA score is reported

Table 11. QI 2c - ASA reported

	QI 2c - ASA reported percentage	
	% (n/N)	95% CI
EFFECT	90.9 (1874/2061)	[89.6, 92.1]





Figure 19. Funnel plot for QI 2c - ASA reported

**2.3. QI 3: Proportion of patients undergoing surgery for whom histological type according to WHO classification is reported/available (from resection specimen) for treatment decision**

**Table 12. QI 3**

	QI 3 percentage	
	% (n/N)	95% CI
EFFECT	95.9 (1794/1871)	[94.9, 96.7]



**Figure 20. Funnel plot for QI 3**

2.4. QI 4: Overall proportion of operated patients who had a pre-operative biopsy

Table 13. QI 4

QI 4 percentage		
	% (n/N)	95% CI
EFFECT	85.6 (1601/1871)	[83.9, 87.1]





Figure 21. Funnel plot for QI 4



**2.5. QI 5: Proportion of patients undergoing surgery for whom tumour grade (1/2/3 or type II) is reported/available (from biopsy) for treatment decision**

**Table 14. QI 5**

	QI 5 percentage	
	% (n/N)	95% CI
EFFECT	83.4 (1491/1787)	[81.6, 85.1]



**Figure 22. Funnel plot for QI 5**

2.6. QI 6: Proportion of patients with clinical stage I undergoing surgery for whom the surgical intervention is a TH/BSO

Table 15. QI 6

	QI 6 percentage	
	% (n/N)	95% CI
EFFECT	75.1 (632/842)	[72.0, 77.9]





Figure 23. Funnel plot for QI 6

**2.7. QI 7: Proportion of patients undergoing surgery for whom adnexal invasion (yes/no) is reported/available (pathology report) for treatment decision**

**Table 16. QI 7**

	QI 7 percentage	
	% (n/N)	95% CI
EFFECT	96.9 (1554/1604)	[95.9, 97.6]



**Figure 24. Funnel plot for QI 7**

2.8. QI 8: Proportion of endometrial carcinoma patients with clinical stage I cancer who were operated by minimally invasive surgery (laparoscopy or robot)

Table 17. QI 8

	QI 8 percentage	
	% (n/N)	95% CI
EFFECT	51.8 (440/849)	[48.5, 55.2]





Figure 25. Funnel plot for QI 8

**2.9. QI 9: Proportion of patients undergoing surgery for whom myometrial invasion is semi-quantitatively or quantitatively reported/available for treatment decision**

**2.9.1. QI 9a: Myometrial invasion available for treatment decision, when analysis resection specimen available**

**Table 18. QI 9a - analysis resection specimen available**

QI 9a - analysis resection specimen available percentage		
	% (n/N)	95% CI
EFFECT	95.6 (1697/1775)	[94.5, 96.5]



**Figure 26. Funnel plot for QI 9a - analysis resection specimen available**

2.9.1. QI 9b: Myometrial invasion available for treatment decision

Table 19. QI 9b - analysis resection specimen not required

QI 9b - analysis resection specimen not required percentage		
	% (n/N)	95% CI
EFFECT	95.0 (1697/1787)	[93.8, 95.9]





Figure 27. Funnel plot for QI 9b - analysis resection specimen not required

**2.10. QI 10: Proportion of patients undergoing surgery, for whom cervical stromal invasion (yes/no) is reported/available (post-operatively) for treatment decision**

**2.10.1. QI 10a: Cervical stromal invasion available for treatment decision, when analysis resection specimen available**

**Table 20. QI 10a - analysis resection specimen available**

	QI 10a - analysis resection specimen available percentage	
	% (n/N)	95% CI
EFFECT	93.8 (1654/1764)	[92.5, 94.8]



**Figure 28. Funnel plot for QI 10a - analysis resection specimen available**

2.10.2. QI 10b: Cervical stromal invasion available for treatment decision

Table 21. QI 10b - analysis resection specimen not required

QI 10b - analysis resection specimen not required percentage		
	% (n/N)	95% CI
EFFECT	93.3 (1654/1772)	[92.1, 94.4]




Figure 29. Funnel plot for QI 10b - analysis resection specimen not required



**2.11. QI 11: Proportion of patients with stage I or II serous or clear cell carcinoma or carcinosarcoma, who had omentectomy**

**Table 22. QI 11**

	QI 11 percentage	
	% (n/N)	95% CI
EFFECT	44.8 (56/125)	[36.3, 53.6]

**2.12. QI 12: Proportion of patients with uterine leiomyosarcoma or endometrial stromal sarcoma who had TH (+/- BSO)**


**Table 23. QI 12**

	QI 12 percentage	
	% (n/N)	95% CI
EFFECT	77.8 (56/72)	[66.8, 85.9]

**2.13. QI 13: Proportion of patients who had para-aortic lymphadenectomy during surgery for whom number of para-aortic lymph nodes with metastasis is specified**

**Table 24. QI 13**

EFFECT	QI 13 percentage	
	% (n/N)	95% CI
EFFECT	88.2 (180/204)	[83.0, 92.0]




**Figure 30. Funnel plot for QI 13**

**2.14. QI 14: Proportion of patients who had lymphadenectomy during surgery for whom localization (pelvic and/or para-aortic) of lymph nodes removed is specified**

**Table 25. QI 14**

EFFECT	QI 14 percentage	
	% (n/N)	95% CI
EFFECT	95.4 (858/899)	[93.9, 96.6]




**Figure 31. Funnel plot for QI 14**

**2.15. QI 15: Proportion of patients who had pelvic lymphadenectomy during surgery for whom number of pelvic lymph nodes harvested is specified**

**Table 26. QI 15**

EFFECT	QI 15 percentage	
	% (n/N)	95% CI
EFFECT	97.0 (815/840)	[95.6, 98.0]




**Figure 32. Funnel plot for QI 15**

**2.16. QI 16: Proportion of patients who had para-aortic lymphadenectomy during surgery for whom the number of para-aortic lymph nodes harvested is specified**

**Table 27. QI 16**

EFFECT	QI 16 percentage	
	% (n/N)	95% CI
EFFECT	94.1 (192/204)	[89.9, 96.6]




**Figure 33. Funnel plot for QI 16**

**2.17. QI 17: Proportion of patients who had pelvic lymphadenectomy during surgery for whom extracapsular extension is specified in case of pelvic lymph node metastasis**

**Table 28. QI 17**

	QI 17 percentage	
	% (n/N)	95% CI
EFFECT	80.4 (119/148)	[73.2, 86.0]



**Figure 34. Funnel plot for QI 17**

**2.18. QI 18: Proportion of patients with stage II disease who had TH/BSO and at least pelvic lymph node dissection**

**Table 29. QI 18**

	QI 18 percentage	
	% (n/N)	95% CI
EFFECT	24.5 (12/49)	[14.5, 38.3]



**2.19. QI 19: Proportion of patients with clinical stage I and grade 3 tumours who had at least pelvic lymphadenectomy**

**Table 30. QI 19**

	QI 19 percentage	
	% (n/N)	95% CI
EFFECT	75.5 (108/143)	[67.8, 81.9]

**2.20. QI 20: Proportion of clinical stage IIIA patients undergoing surgery who had TH/BSO and pelvic and para-aortic lymphadenectomy**

**Table 31. QI 20**

	QI 20 percentage	
	% (n/N)	95% CI
EFFECT	10.0 (1/10)	[1.4, 46.7]

2.21. QI 21: Proportion of patients with tumour invading less than 50% of the myometrium and grade 1 tumours, who had lymphadenectomy

Table 32. QI 21

EFFECT	QI 21 percentage	
	% (n/N)	95% CI
EFFECT	23.5 (115/490)	[19.9, 27.4]




Figure 35. Funnel plot for QI 21

**2.22. QI 22: Proportion of patients with stage I or II serous or clear cell carcinoma or carcinosarcoma, who had at least pelvic lymphadenectomy**

**Table 33. QI 22**

	QI 22 percentage	
	% (n/N)	95% CI
EFFECT	60.0 (75/125)	[51.2, 68.2]

**2.23. QI 23: Proportion of patients with uterine leiomyosarcoma or endometrial stromal sarcoma (low grade) who had lymphadenectomy**

**Table 34. QI 23**

	QI 23 percentage	
	% (n/N)	95% CI
EFFECT	7.1 (4/56)	[2.7, 17.5]

**2.24. QI 24: Proportion of patients with metastatic or recurrent endometrioid adenocarcinoma for whom hormone receptors were assessed in the pathology report**

**2.24.1. QI 24a: pM=1 patients**

**Table 35. QI 24a - pM=1**

	QI 24a - pM=1 percentage	
	% (n/N)	95% CI
EFFECT	56.3 (9/16)	[32.4, 77.5]

**2.24.2. QI 24b: cM=1 patients****Table 36. QI 24b - cM=1**

	QI 24b - cM=1 percentage	
	% (n/N)	95% CI
EFFECT	55.2 (16/29)	[37.2, 71.9]

**2.25. QI 25: Proportion of patients with endometrial stromal sarcomas undergoing surgery for whom receptor status (ER and PR) has been assessed and reported/available for treatment decision**

**Table 37. QI 25**

	QI 25 percentage	
	% (n/N)	95% CI
EFFECT	48.5 (16/33)	[32.2, 65.1]




**2.26. QI 26: Proportion of operated patients receiving subsequent/adjvant anticancer treatment, if any, with a maximum waiting time of 60 days (between date of surgery and date of first session of radiotherapy or chemotherapy).**

**2.26.1. QI 26a: Proportion of operated patients receiving subsequent/adjvant anticancer treatment**

**Table 38. QI 26a**

	QI 26a percentage	
	% (n/N)	95% CI
EFFECT	34.1 (376/1102)	[31.4, 37.0]




**Figure 36. Funnel plot for QI 26a**

**2.26.1. QI 26b: Proportion of operated patients receiving subsequent/adjuvant anticancer treatment, if any, with a maximum waiting time of 60 days (between date of surgery and date of first session of radiotherapy or chemotherapy).**

**Table 39. QI 26b**

	QI 26b percentage	
	% (n/N)	95% CI
EFFECT	68.9 (259/376)	[64.0, 73.4]



**Figure 37. Funnel plot for QI 26b**

2.27. QI 27: Proportion of patients who received external radiotherapy as adjuvant treatment for whom the technique was IMRT or 3DCRT

Table 40. QI 27

	QI 27 percentage	
	% (n/N)	95% CI
EFFECT	50.0 (81/162)	[42.4, 57.6]




Figure 38. Funnel plot for QI 27

**2.28. QI 28: Proportion of patients with clinical stage I and II cancer who were not operated who received radiotherapy (intra-uterine brachytherapy +/- pelvic radiotherapy)**

The calculation of this indicator requires information from the IMA database form which only data until the incidence year 2013 is available (2 years delay). As the patient selection for this indicator only includes 16 patients up to date, results for this indicator will not be available until the next feedback document.

**2.29. QI 29: Proportion of pathological stage I patients with at least 2 of the following 3 risk factors (age  $\geq$  60 years, > 50% invasion of myometrium or grade 3) who were operated but did not have lymphadenectomy, who received adjuvant radiotherapy (EBRT or brachy)**

**Table 41. QI 29**

	QI 29 percentage	
	% (n/N)	95% CI
EFFECT	33.3 (24/72)	[23.4, 44.9]

**2.30. QI 30: Proportion of pathological stage I patients with at least 2 of the following 3 risk factors (age  $\geq$  60 years, > 50% invasion of myometrium or grade 3) who received adjuvant radiotherapy for whom radiotherapy was vaginal brachytherapy**


**Table 42. QI 30**

	QI 30 percentage	
	% (n/N)	95% CI
EFFECT	84.1 (90/107)	[75.9, 89.9]

**2.31. QI 31: Proportion of operated patients without risk factors for recurrence (stage IA and Grade 1 or 2) who received any form of post-operative radiotherapy**

**Table 43. QI 31**

	QI 31 percentage	
	% (n/N)	95% CI
EFFECT	5.2 (22/424)	[3.4, 7.8]



**Figure 39. Funnel plot for QI 31**

**2.32. QI 32: Proportion of operated patients with stage I and low grade endometrial stromal sarcoma or leiomyosarcoma who received radiotherapy**

**Table 44. QI 32**

	QI 32 percentage	
	% (n/N)	95% CI
EFFECT	17.6 (3/17)	[5.8, 42.7]



2.33. QI 33: Proportion of patients who received postoperative adjuvant chemotherapy for whom regimen included platinum-based drugs

Table 45. QI 33

	QI 33 percentage	
	% (n/N)	95% CI
EFFECT	93.6 (146/156)	[88.5, 96.5]




Figure 40. Funnel plot for QI 33

**2.34. QI 34: Proportion of patients with advanced cancer (pathological stages III and IVa) who underwent surgery who received chemotherapy**

**Table 46. QI 34**

	QI 34 percentage	
	% (n/N)	95% CI
EFFECT	60.9 (78/128)	[52.2, 69.0]

**2.35. QI 35: Proportion of pathological stage I patients with at least 2 of the following 3 risk factors (age  $\geq$  60 years, > 50% invasion of myometrium or grade 3) who were operated but did not have lymphadenectomy, who received adjuvant chemotherapy**


**Table 47. QI 35**

	QI 35 percentage	
	% (n/N)	95% CI
EFFECT	8.3 (6/72)	[3.8, 17.3]

**2.36. QI 36: Proportion of operated patients at low risk of recurrence (pathological stage IA and grade 1 or 2) who received post-operative adjuvant chemotherapy**

**Table 48. QI 36**

	QI 36 percentage	
	% (n/N)	95% CI
EFFECT	0.7 (3/424)	[0.2, 2.2]



**Figure 41. Funnel plot for QI 36**

**2.37. QI 37: Proportion of patients with endometrioid (stage IVB) adenocarcinoma cancer with positive hormonal receptors, who receive hormone therapy (progesterone or AI)**

**Table 49. QI 37**

	QI 37 percentage	
	% (n/N)	95% CI
EFFECT	0.0 (0/4)	–

**2.38. QI 38: Proportion of operated patients with clinical or pathological stage II to IV endometrial stromal sarcomas who received post-operative hormone treatment**

**Table 50. QI 38**

	QI 38 percentage	
	% (n/N)	95% CI
EFFECT	0.0 (0/2)	—

2.39. QI 39: Proportion of patients operated who died within the 30 days after the operation (30-day mortality)

Table 51. QI 39

QI 39 percentage		
	% (n/N)	95% CI
EFFECT	0.4 (8/1871)	[0.2, 0.9]




Figure 42. Funnel plot for QI 39

## 2.40. QI 40: Observed survival proportion

Estimates for observed survival proportion are given for strata with at least 20 eligible patients and sufficient follow-up time.


**Table 52. Unadjusted observed survival stratified by patient and tumour characteristics, overall EFFECT result.**

Characteristic	Unadjusted Observed Survival (%)		
	EFFECT		
	Number at risk	1 year	3 year
<b>Overall</b>	2,048	89.6 [88.2, 90.9]	78.5 [76.0, 80.8]
<b>Age Category</b>			
<55 yr	218	94.9 [90.7, 97.2]	90.1 [83.6, 94.1]
55-64 yr	514	94.7 [92.3, 96.4]	87.7 [83.5, 91.0]
65-74 yr	648	92.1 [89.6, 94.0]	82.1 [77.5, 85.8]
≥75 yr	668	81.7 [78.3, 84.5]	63.7 [58.2, 68.7]
<b>Histology</b>			
Unspecified	6	NA (N<20)	NA (N<20)
Carcinomas	1,947	90.3 [88.8, 91.6]	79.0 [76.4, 81.4]
Sarcomas	95	80.0 [70.0, 86.9]	72.7 [60.9, 81.5]
<b>Surgery</b>			
Yes	1,864	94.2 [93.0, 95.2]	83.3 [80.7, 85.6]
No	184	42.7 [35.0, 50.2]	28.7 [20.8, 37.1]
<b>Clinical Stage</b>			
<i>Carcinomas</i>			
Not mentioned	679	89.0 [86.3, 91.3]	77.7 [73.1, 81.5]
Stage X	183	93.2 [88.3, 96.1]	81.7 [71.5, 88.5]
Stage 0	2	NA (N<20)	NA (N<20)
cT0	5	NA (N<20)	NA (N<20)
Stage I	848	96.1 [94.4, 97.2]	87.1 [83.4, 90.0]
Stage II	49	76.7 [61.0, 86.8]	68.8 [50.5, 81.5]
Stage III	107	83.7 [74.8, 89.7]	58.1 [42.1, 71.1]
Stage IV	74	47.6 [35.4, 58.7]	30.9 [19.2, 43.3]
<i>Sarcomas</i>			
Not mentioned	62	84.3 [71.8, 91.5]	76.3 [61.2, 86.2]
Stage X	5	NA (N<20)	NA (N<20)
Stage I	14	NA (N<20)	NA (N<20)
Stage II	4	NA (N<20)	NA (N<20)
Stage III	3	NA (N<20)	NA (N<20)
Stage IV	7	NA (N<20)	NA (N<20)
<b>Pathological Stage</b>			
<i>Carcinomas</i>			



Characteristic	Unadjusted Observed Survival (%)		
	Number at risk	EFFECT	
		1 year	3 year
Not mentioned	251	58.7 [52.0, 64.9]	45.4 [37.1, 53.3]
Stage X	7	NA (N<20)	NA (N<20)
Stage 0	2	NA (N<20)	NA (N<20)
Stage I	1,317	97.5 [96.5, 98.3]	89.0 [86.2, 91.3]
Stage II	102	93.8 [86.6, 97.1]	79.9 [67.2, 88.1]
Stage III	219	83.6 [77.5, 88.2]	62.0 [52.5, 70.1]
Stage IV	49	74.2 [59.0, 84.5]	49.4 [29.0, 66.9]
<i>Sarcomas</i>			
Not mentioned	38	74.9 [57.2, 86.1]	71.5 [53.3, 83.6]
Stage I	44	88.3 [74.1, 95.0]	76.9 [57.7, 88.2]
Stage II	5	NA (N<20)	NA (N<20)
Stage III	4	NA (N<20)	NA (N<20)
Stage IV	4	NA (N<20)	NA (N<20)

Only hospitals with at least 20 eligible patients and a minimum follow-up of 1 year are displayed on the graph.



**Figure 43. Funnel plot of the estimated 1-year observed survival proportion by hospital.**

## 2.41. QI 41: Proportion of patients who are alive without uterine cancer 1 year after their diagnosis (1-year disease free survival)


Only patients with at least one FU form registered are taken into account for the estimation of the disease-free survival. Estimates for disease-free survival proportion are given for strata with at least 20 eligible patients and sufficient follow-up time.

**Table 53. Unadjusted disease-free survival stratified by patient and tumour characteristics, overall EFFECT result.**

Characteristic	Unadjusted Disease-free Survival (%)	
	EFFECT	
	Number at risk	1 year
<b>Overall</b>	1,213	81.3 [78.7, 83.6]
<b>Age Category</b>		.
<55 yr	128	86.5 [78.1, 91.9]
55-64 yr	306	87.3 [82.5, 90.8]
65-74 yr	379	86.1 [81.7, 89.5]
≥75 yr	400	70.2 [64.7, 74.9]
<b>Histology</b>		.
Unspecified	6	NA (N<20)
Carcinomas	1,159	82.8 [80.2, 85.0]
Sarcomas	48	55.7 [38.5, 69.8]
<b>Surgery</b>		.
Yes	1,114	87.1 [84.7, 89.2]
No	99	24.5 [16.4, 33.6]
<b>Clinical Stage</b>		.
<b>Carcinomas</b>		.
Not mentioned	379	90.9 [87.5, 93.4]
Stage X	133	92.5 [86.4, 95.9]
Stage 0	1	NA (N<20)
cT0	2	NA (N<20)
Stage I	494	95.9 [93.7, 97.3]
Stage II	31	72.8 [52.8, 85.4]
Stage III	64	87.4 [76.5, 93.5]
Stage IV	52	50.7 [36.2, 63.5]
<b>Sarcomas</b>		.
Not mentioned	29	82.4 [62.7, 92.3]
Stage X	4	NA (N<20)
Stage I	7	NA (N<20)
Stage II	2	NA (N<20)
Stage III	2	NA (N<20)

Characteristic	Unadjusted Disease-free Survival (%) EFFECT	
	Number at risk	1 year
Stage IV	3	NA (N<20)
<b><i>Pathological Stage</i></b>		
<i>Carcinomas</i>		
Not mentioned	142	62.9 [54.3, 70.3]
Stage X	5	NA (N<20)
Stage 0	1	NA (N<20)
Stage I	777	97.4 [96.0, 98.3]
Stage II	70	94.1 [85.1, 97.8]
Stage III	127	81.5 [73.4, 87.3]
Stage IV	34	81.8 [63.9, 91.4]
<i>Sarcomas</i>		
Not mentioned	20	75.0 [50.0, 88.7]
Stage I	24	91.5 [70.0, 97.8]
Stage III	1	NA (N<20)
Stage IV	2	NA (N<20)

Only hospitals with at least 20 eligible patients and a minimum follow-up of 1 year are displayed on the graph.



**Figure 44. Funnel plot of the estimated 1-year disease-free survival proportion by hospital.**